Aytu BioScience Inc.Find Ratings Reports
AYTU BIOSCIENCE INC's gross profit margin for the third quarter of its fiscal year 2020 is essentially unchanged when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its subsector. AYTU BIOSCIENCE INC has strong liquidity. Currently, the Quick Ratio is 1.73 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 434.41% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY20||Q3 FY19|
|Net Sales ($mil)||8.16||2.38|
|Net Income ($mil)||-5.33||-4.5|
|Balance Sheet||Q3 FY20||Q3 FY19|
|Cash & Equiv. ($mil)||62.52||14.75|
|Total Assets ($mil)||158.95||38.34|
|Total Debt ($mil)||12.87||5.14|
|Profitability||Q3 FY20||Q3 FY19|
|Gross Profit Margin||75.8||74.68|
|Return on Assets||-15.73||-31.43|
|Return on Equity||-29.17||-75.15|
|Debt||Q3 FY20||Q3 FY19|
|Share Data||Q3 FY20||Q3 FY19|
|Shares outstanding (mil)||100.61||12.85|
|Div / share||0.0||0.0|
|Book value / share||0.85||1.25|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1.4287108E7||1.5134851E7|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.77 indicates a significant discount versus the S&P 500 average of 3.29 and a significant discount versus the subsector average of 10.77. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, AYTU BIOSCIENCE INC proves to trade at a discount to investment alternatives.
|AYTU NM||Peers 35.90||AYTU NM||Peers 20.24|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AYTU's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AYTU's P/CF is negative making the measure meaningless.
|AYTU 37.75||Peers 17.33||AYTU NA||Peers 0.70|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
AYTU's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AYTU 1.77||Peers 10.77||AYTU 44.97||Peers 9.04|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AYTU is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
AYTU is expected to have an earnings growth rate that significantly exceeds its peers.
|AYTU 10.48||Peers 12.63||AYTU 121.83||Peers 12.45|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AYTU is trading at a discount to its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
AYTU has a sales growth rate that significantly exceeds its peers.